TY - JOUR T1 - Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases JF - medRxiv DO - 10.1101/2021.05.19.21257450 SP - 2021.05.19.21257450 AU - Daniel Clemente AU - Clara Udaondo AU - Jaime de Inocencio AU - Juan Carlos Nieto AU - Pilar Galán del Río AU - Antía García Fernández AU - Jaime Arroyo Palomo AU - Javier Bachiller-Corral AU - Juan Carlos Lopez Robledillo AU - Leticia Leon AU - Lydia Abasolo AU - Alina Boteanu Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/20/2021.05.19.21257450.abstract N2 - Background This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in pediatric patients with rheumatic and musculoskeletal diseases (RMD) and identify the risk factors associated with symptomatic or severe disease defined as hospital admission, intensive care admission or death.Methods An observational longitudinal study was conducted during the first year of pandemic SARS-CoV-2 (1st March 2020 to 1st March 2021). All pediatric patients attended at the rheumatology outpatient clinic of six tertiary hospital in Madrid, Spain, with a medical diagnosis of RMD and COVID-19 were included. Main outcomes were symptomatic disease and hospital admission. The covariates were sociodemographic, clinical, and treatments. We ran a multivariable logistic regression model to assess risk factors for outcomes.Results The study population included 77 pediatric patients. Mean age was 11.88 (4.04) years Of these, 30 patients were asymptomatic, 41 had a mild or moderate disease and other 6 patients (7.79%) required hospital admission related to COVID-19. The median length of stay was 5 (2–20) days and there was no death. Previous comorbidities increased the risk for symptomatic disease and hospital admission. Compared with outpatients, the factor independently associated with hospital admission was the use of glucocorticoids (OR 1.08; p=0.00). No statistically significant findings for symptomatic COVID-19 were found in the final model.Conclusion Our data found no differences in COVID-19 outcomes between children-onset rheumatic diseases. Our results suggest that associated comorbidities and being in treatment with glucocorticoids increase the risk of hospital admission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Hospital Ramon y Cajal Institutional Ethics Committee (approval number 136-20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and analyzed for the present study are available from the corresponding author on reasonable request.ACEangiotensin-converting-enzyme inhibitorsCAPScryopyrin-associated periodic syndromeCOVID-19Coronavirus disease 2019DMARDdisease-modifying anti-rheumatic drug csDMARDsclassic DMARDsts/bDMARDstargeted synthetic or biologic DMARDsFMFfamilial Mediterranean feverJAKJanus-KinasaJIAjuvenile idiopathic arthritisHIDShyperimmunoglobulin-D syndromeIQRinterquartile RangeMIS-Cmultisystem inflammatory syndrome in childrenMKDmevalonate kinase deficiencyNSAIDnonsteroidal anti-inflammatory drugsPCRpolymerase chain reactionPFAPAperiodic fever, adenopathy, pharyngitis and aphthous stomatitisRMDrheumatic and musculoskeletal diseasesSARSsevere acute respiratory syndromeTNFtumor necrosis factorTRAPSTNF- receptor associated periodic syndrome ER -